静脉地塞米松预防长效椎管内阿片类药物术后恶心呕吐的系统综述与荟萃分析
本系统综述与荟萃分析评估静脉地塞米松对接受长效椎管内阿片类药物患者的术后恶心呕吐预防效果。
要点
- 静脉地塞米松可减少长效椎管内阿片类药物患者术后24h补救止吐药需求。
- 低剂量与中剂量地塞米松、手术开始或结束给药、鞘内或硬膜外途径间疗效无差异。
- 地塞米松组未报告感染或烦躁不安,但无试验监测血糖水平。
核心结论
- 静脉地塞米松在接受长效椎管内阿片类药物的患者中,术后24小时内提供有效的止吐预防。
研究设计与样本
- 主要结局为术后24小时内补救止吐药需求,按地塞米松剂量(低剂量2.5-5.0 mg;中剂量6.0-10.0 mg)、给药时机(手术开始或结束)及长效阿片给药途径(鞘内或硬膜外)分析。
主要发现
- 与安慰剂相比,静脉地塞米松减少补救止吐药需求(风险比(95%CI)0.44(0.35-0.56);I2=43%;p<0.00001;GRADE证据质量:中等)。
- 地塞米松剂量亚组差异p=0.67,给药时机亚组差异p=0.32,长效阿片给药途径亚组差异p=0.10,均无统计学差异。
- 在检索这些并发症的试验中,无患者发生感染或烦躁不安;无试验测量血糖水平。
关键数值与推荐
- 静脉地塞米松与安慰剂相比,补救止吐药需求的风险比(95%CI)为0.44(0.35-0.56),I2=43%,p<0.00001,GRADE证据质量中等。
- 地塞米松剂量亚组差异p=0.67,给药时机亚组差异p=0.32,长效阿片给药途径亚组差异p=0.10。
临床怎么用
- 对接受长效椎管内阿片类药物的手术患者,可考虑静脉给予地塞米松以预防术后24小时内恶心呕吐。
- 低剂量(2.5-5.0 mg)与中剂量(6.0-10.0 mg)疗效无差异,给药时机和椎管内途径不影响疗效。
局限性
- 无试验测量血糖水平,无法评估高血糖风险。
- 仅部分试验检索了感染和烦躁不安,相关安全性数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Long-acting neuraxial opioids provide excellent analgesia after surgery, but are associated with higher rates of postoperative nausea and vomiting. Dexamethasone effectively prevents postoperative nausea and vomiting after general anaesthesia, but its value in patients receiving long-acting neuraxial opioids is undetermined. Therefore, the objective of this meta-analysis was to assess the prophylactic anti-emetic efficacy of intravenous (i.v.) dexamethasone in this population. The study methodology followed the PRISMA statement guidelines. The primary outcome was the need for rescue anti-emetics during the first 24 postoperative hours, analysed according to the dose of dexamethasone (low-dose 2.5-5.0 mg; intermediate dose 6.0-10.0 mg), timing of administration (beginning or end of surgery) and route of long-acting opioid administration (intrathecal or epidural). Additionally, the rates of complications (restlessness, infection, hyperglycaemia) were sought. Thirteen trials were identified, representing a total of 1111 patients. When compared with placebo, intravenous dexamethasone reduced the need for rescue anti-emetics (risk ratio (95%CI) 0.44 (0.35-0.56); I2 = 43%; p < 0.00001; quality of GRADE evidence: moderate), without differences between dexamethasone doses (p for sub-group difference = 0.67), timing of administration (p for sub-group difference = 0.32) or route of long-acting opioid (p for sub-group difference = 0.10). No patients developed infection or restlessness among trials that sought these complications. No trial measured blood glucose levels. In conclusion, there is enough evidence to state that intravenous dexamethasone provides effective anti-emetic prophylaxis during the first 24 postoperative hours in patients who receive long-acting neuraxial opioids.
引用
- Grape S, Usmanova I, Kirkham KR, et al. Intravenous dexamethasone for prophylaxis of postoperative nausea and vomiting after administration of long-acting neuraxial opioids: a systematic review and meta-analysis. Anaesthesia. 2017. PMID: 29226971. doi:10.1111/anae.14166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。